Alleviation of experimental hemiparkinsonism by high‐frequency stimulation of the subthalamic nucleus in primates: A comparison with L‐dopa treatment
Identifieur interne : 004629 ( Main/Exploration ); précédent : 004628; suivant : 004630Alleviation of experimental hemiparkinsonism by high‐frequency stimulation of the subthalamic nucleus in primates: A comparison with L‐dopa treatment
Auteurs : Abdelhamid Benazzouz [France] ; Thomas Boraud [France] ; Jean Féger [France] ; Pierre Burbaud [France] ; Bernard Bioulac [France] ; Christian Gross [France]Source :
- Movement Disorders [ 0885-3185 ] ; 1996-11.
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Animals, Antiparkinson Agents (pharmacology), Dominance, Cerebral (drug effects), Dominance, Cerebral (physiology), Electric Stimulation Therapy, Electromyography (drug effects), High‐frequency stimulation, Levodopa (pharmacology), MPTP, Macaca mulatta, Motor Skills (drug effects), Motor Skills (physiology), Neurologic Examination (drug effects), Parkinson Disease, Secondary (chemically induced), Parkinson Disease, Secondary (physiopathology), Parkinsonism, Subthalamic nucleus, Thalamic Nuclei (drug effects), Thalamic Nuclei (physiopathology).
- MESH :
- chemical , pharmacology : Antiparkinson Agents, Levodopa.
- chemical : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
- chemically induced : Parkinson Disease, Secondary.
- drug effects : Dominance, Cerebral, Electromyography, Motor Skills, Neurologic Examination, Thalamic Nuclei.
- physiology : Dominance, Cerebral, Motor Skills.
- physiopathology : Parkinson Disease, Secondary, Thalamic Nuclei.
- Animals, Electric Stimulation Therapy, Macaca mulatta.
Abstract
Experimental studies in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐treated monkeys have shown that akinesia and rigidity are linked to a hyperactivity of glutamatergic subthalamic nucleus neurons and that the lesion of this nucleus can ameliorate parkinsonian motor signs. In our study, high‐frequency stimulation applied at the subthalamic level was performed on two Macaca mulatta monkeys rendered hemiparkinsonian by unilateral infusion of MPTP. Its effects on rigidity and bradykinesia have been quantified. The results exhibit an important alleviation of both symptoms during the application of subthalamic stimulation comparable to that obtained during L‐Dopa treatment, but without the appearance of abnormal movements such hemiballism or dyskinesia. Our data show that subthalamic stimulation has a beneficial effect on experimental parkinsonian rigidity and bradykinesia and suggests a new therapy approach for the treatment of Parkinson's disease by using subthalamic high‐frequency stimulation instead of L‐Dopa treatment.
Url:
DOI: 10.1002/mds.870110606
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000811
- to stream Istex, to step Curation: 000811
- to stream Istex, to step Checkpoint: 001816
- to stream PubMed, to step Corpus: 001561
- to stream PubMed, to step Curation: 001520
- to stream PubMed, to step Checkpoint: 001520
- to stream Ncbi, to step Merge: 001E35
- to stream Ncbi, to step Curation: 001E35
- to stream Ncbi, to step Checkpoint: 001E35
- to stream Main, to step Merge: 004E99
- to stream Main, to step Curation: 004629
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Alleviation of experimental hemiparkinsonism by high‐frequency stimulation of the subthalamic nucleus in primates: A comparison with L‐dopa treatment</title><author><name sortKey="Benazzouz, Abdelhamid" sort="Benazzouz, Abdelhamid" uniqKey="Benazzouz A" first="Abdelhamid" last="Benazzouz">Abdelhamid Benazzouz</name></author><author><name sortKey="Boraud, Thomas" sort="Boraud, Thomas" uniqKey="Boraud T" first="Thomas" last="Boraud">Thomas Boraud</name></author><author><name sortKey="Feger, Jean" sort="Feger, Jean" uniqKey="Feger J" first="Jean" last="Féger">Jean Féger</name></author><author><name sortKey="Burbaud, Pierre" sort="Burbaud, Pierre" uniqKey="Burbaud P" first="Pierre" last="Burbaud">Pierre Burbaud</name></author><author><name sortKey="Bioulac, Bernard" sort="Bioulac, Bernard" uniqKey="Bioulac B" first="Bernard" last="Bioulac">Bernard Bioulac</name></author><author><name sortKey="Gross, Christian" sort="Gross, Christian" uniqKey="Gross C" first="Christian" last="Gross">Christian Gross</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:AA534287B555AF33E66A45B2FEB19234D8573FB5</idno><date when="1996" year="1996">1996</date><idno type="doi">10.1002/mds.870110606</idno><idno type="url">https://api.istex.fr/document/AA534287B555AF33E66A45B2FEB19234D8573FB5/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000811</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000811</idno><idno type="wicri:Area/Istex/Curation">000811</idno><idno type="wicri:Area/Istex/Checkpoint">001816</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001816</idno><idno type="wicri:doubleKey">0885-3185:1996:Benazzouz A:alleviation:of:experimental</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:8914087</idno><idno type="wicri:Area/PubMed/Corpus">001561</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001561</idno><idno type="wicri:Area/PubMed/Curation">001520</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001520</idno><idno type="wicri:Area/PubMed/Checkpoint">001520</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001520</idno><idno type="wicri:Area/Ncbi/Merge">001E35</idno><idno type="wicri:Area/Ncbi/Curation">001E35</idno><idno type="wicri:Area/Ncbi/Checkpoint">001E35</idno><idno type="wicri:doubleKey">0885-3185:1996:Benazzouz A:alleviation:of:experimental</idno><idno type="wicri:Area/Main/Merge">004E99</idno><idno type="wicri:Area/Main/Curation">004629</idno><idno type="wicri:Area/Main/Exploration">004629</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Alleviation of experimental hemiparkinsonism by high‐frequency stimulation of the subthalamic nucleus in primates: A comparison with L‐dopa treatment</title><author><name sortKey="Benazzouz, Abdelhamid" sort="Benazzouz, Abdelhamid" uniqKey="Benazzouz A" first="Abdelhamid" last="Benazzouz">Abdelhamid Benazzouz</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de Neurophysiologie, CNRS URA 1200, Université de Bordeaux II, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Boraud, Thomas" sort="Boraud, Thomas" uniqKey="Boraud T" first="Thomas" last="Boraud">Thomas Boraud</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de Neurophysiologie, CNRS URA 1200, Université de Bordeaux II, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Feger, Jean" sort="Feger, Jean" uniqKey="Feger J" first="Jean" last="Féger">Jean Féger</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de Pharmacologie, Université R. Descartes, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Burbaud, Pierre" sort="Burbaud, Pierre" uniqKey="Burbaud P" first="Pierre" last="Burbaud">Pierre Burbaud</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de Neurophysiologie, CNRS URA 1200, Université de Bordeaux II, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Bioulac, Bernard" sort="Bioulac, Bernard" uniqKey="Bioulac B" first="Bernard" last="Bioulac">Bernard Bioulac</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de Neurophysiologie, CNRS URA 1200, Université de Bordeaux II, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Gross, Christian" sort="Gross, Christian" uniqKey="Gross C" first="Christian" last="Gross">Christian Gross</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de Neurophysiologie, CNRS URA 1200, Université de Bordeaux II, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de Neurophysiologie, CNRS URA 1200, Université de Bordeaux II, 146, rue Léo Saignat 33076 Bordeaux Cedex</wicri:regionArea><placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region><region type="old region" nuts="2">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1996-11">1996-11</date><biblScope unit="volume">11</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="627">627</biblScope><biblScope unit="page" to="632">632</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">AA534287B555AF33E66A45B2FEB19234D8573FB5</idno><idno type="DOI">10.1002/mds.870110606</idno><idno type="ArticleID">MDS870110606</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Animals</term><term>Antiparkinson Agents (pharmacology)</term><term>Dominance, Cerebral (drug effects)</term><term>Dominance, Cerebral (physiology)</term><term>Electric Stimulation Therapy</term><term>Electromyography (drug effects)</term><term>High‐frequency stimulation</term><term>Levodopa (pharmacology)</term><term>MPTP</term><term>Macaca mulatta</term><term>Motor Skills (drug effects)</term><term>Motor Skills (physiology)</term><term>Neurologic Examination (drug effects)</term><term>Parkinson Disease, Secondary (chemically induced)</term><term>Parkinson Disease, Secondary (physiopathology)</term><term>Parkinsonism</term><term>Subthalamic nucleus</term><term>Thalamic Nuclei (drug effects)</term><term>Thalamic Nuclei (physiopathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Dominance, Cerebral</term><term>Electromyography</term><term>Motor Skills</term><term>Neurologic Examination</term><term>Thalamic Nuclei</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Dominance, Cerebral</term><term>Motor Skills</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease, Secondary</term><term>Thalamic Nuclei</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Electric Stimulation Therapy</term><term>Macaca mulatta</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Experimental studies in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐treated monkeys have shown that akinesia and rigidity are linked to a hyperactivity of glutamatergic subthalamic nucleus neurons and that the lesion of this nucleus can ameliorate parkinsonian motor signs. In our study, high‐frequency stimulation applied at the subthalamic level was performed on two Macaca mulatta monkeys rendered hemiparkinsonian by unilateral infusion of MPTP. Its effects on rigidity and bradykinesia have been quantified. The results exhibit an important alleviation of both symptoms during the application of subthalamic stimulation comparable to that obtained during L‐Dopa treatment, but without the appearance of abnormal movements such hemiballism or dyskinesia. Our data show that subthalamic stimulation has a beneficial effect on experimental parkinsonian rigidity and bradykinesia and suggests a new therapy approach for the treatment of Parkinson's disease by using subthalamic high‐frequency stimulation instead of L‐Dopa treatment.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Aquitaine</li><li>Nouvelle-Aquitaine</li><li>Île-de-France</li></region><settlement><li>Bordeaux</li><li>Paris</li></settlement></list><tree><country name="France"><region name="Nouvelle-Aquitaine"><name sortKey="Benazzouz, Abdelhamid" sort="Benazzouz, Abdelhamid" uniqKey="Benazzouz A" first="Abdelhamid" last="Benazzouz">Abdelhamid Benazzouz</name></region><name sortKey="Bioulac, Bernard" sort="Bioulac, Bernard" uniqKey="Bioulac B" first="Bernard" last="Bioulac">Bernard Bioulac</name><name sortKey="Boraud, Thomas" sort="Boraud, Thomas" uniqKey="Boraud T" first="Thomas" last="Boraud">Thomas Boraud</name><name sortKey="Burbaud, Pierre" sort="Burbaud, Pierre" uniqKey="Burbaud P" first="Pierre" last="Burbaud">Pierre Burbaud</name><name sortKey="Feger, Jean" sort="Feger, Jean" uniqKey="Feger J" first="Jean" last="Féger">Jean Féger</name><name sortKey="Gross, Christian" sort="Gross, Christian" uniqKey="Gross C" first="Christian" last="Gross">Christian Gross</name><name sortKey="Gross, Christian" sort="Gross, Christian" uniqKey="Gross C" first="Christian" last="Gross">Christian Gross</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004629 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004629 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:AA534287B555AF33E66A45B2FEB19234D8573FB5
|texte= Alleviation of experimental hemiparkinsonism by high‐frequency stimulation of the subthalamic nucleus in primates: A comparison with L‐dopa treatment
}}
| This area was generated with Dilib version V0.6.29. |  |